David R Raleigh1, David A Solomon1, Shane A Lloyd1, Ann Lazar1, Michael A Garcia1, Penny K Sneed1, Jennifer L Clarke1, Michael W McDermott1, Mitchel S Berger1, Tarik Tihan1, Daphne A Haas-Kogan2. 1. Department of Radiation Oncology, University of California San Francisco, San Francisco, California (D.R.R., S.A.L., A.L., M.A.G., P.K.S., D.A.H.-K.); Division of Neuropathology, Department of Pathology, University of California San Francisco, San Francisco, California (D.A.S., T.T.); Department of Neurology, University of California San Francisco, San Francisco, California (J.L.C.); Department of Neurologic Surgery, University of California San Francisco, San Francisco, California (J.L.C., M.W.M., M.S.B.). 2. Department of Radiation Oncology, University of California San Francisco, San Francisco, California (D.R.R., S.A.L., A.L., M.A.G., P.K.S., D.A.H.-K.); Division of Neuropathology, Department of Pathology, University of California San Francisco, San Francisco, California (D.A.S., T.T.); Department of Neurology, University of California San Francisco, San Francisco, California (J.L.C.); Department of Neurologic Surgery, University of California San Francisco, San Francisco, California (J.L.C., M.W.M., M.S.B.) dhaas-kogan@lroc.harvard.edu.
Abstract
BACKGROUND: Pineal parenchymal tumors (PPTs) are rare neoplasms of the central nervous system, and data concerning clinical outcomes are limited. The purpose of this study was to define the clinical behavior of PPT according to current histopathologic criteria and identify prognostic factors to guide therapeutic decisions. METHODS: Seventy-five patients treated for PPT at a single institution between 1992 and 2015 were retrospectively identified. Forty-five resection specimens were available and re-reviewed. Freedom from progression (FFP) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using log-rank tests. RESULTS: Median follow-up was 4.1 years. All patients initially underwent surgery; 78% of patients with PPT of intermediate differentiation (PPTID) and all patients with pineoblastoma received adjuvant therapy. Pathologic re-review refined classification in 27% of cases, with the majority of these being adult patients with pineal tumors originally classified as pineoblastomas that more accurately resembled PPTID based on the 2007 WHO classification. CLASSIFICATION: Our histologic review also identified that PPTIDs can be classified into small-cell and large-cell morphologic subtypes, which have distinct clinical outcomes. Tumor grade, extent of resection, and neuraxis spread were prognostic for FFP. PPTID subtype, extent of resection, and neuraxis spread were prognostic for OS. Genetic analysis of a pineoblastoma case identified somatic mutations of DICER1, ARID1A, and KDM5C genes. CONCLUSIONS: PPTIDs can be classified into 1 of 2 novel morphologic subtypes that are associated with distinct clinical outcomes. Tumor grade, neuraxis spread, and extent of resection also influence outcome for patients with PPT. Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Pineal parenchymal tumors (PPTs) are rare neoplasms of the central nervous system, and data concerning clinical outcomes are limited. The purpose of this study was to define the clinical behavior of PPT according to current histopathologic criteria and identify prognostic factors to guide therapeutic decisions. METHODS: Seventy-five patients treated for PPT at a single institution between 1992 and 2015 were retrospectively identified. Forty-five resection specimens were available and re-reviewed. Freedom from progression (FFP) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using log-rank tests. RESULTS: Median follow-up was 4.1 years. All patients initially underwent surgery; 78% of patients with PPT of intermediate differentiation (PPTID) and all patients with pineoblastoma received adjuvant therapy. Pathologic re-review refined classification in 27% of cases, with the majority of these being adult patients with pineal tumors originally classified as pineoblastomas that more accurately resembled PPTID based on the 2007 WHO classification. CLASSIFICATION: Our histologic review also identified that PPTIDs can be classified into small-cell and large-cell morphologic subtypes, which have distinct clinical outcomes. Tumor grade, extent of resection, and neuraxis spread were prognostic for FFP. PPTID subtype, extent of resection, and neuraxis spread were prognostic for OS. Genetic analysis of a pineoblastoma case identified somatic mutations of DICER1, ARID1A, and KDM5C genes. CONCLUSIONS: PPTIDs can be classified into 1 of 2 novel morphologic subtypes that are associated with distinct clinical outcomes. Tumor grade, neuraxis spread, and extent of resection also influence outcome for patients with PPT. Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: André O von Bueren; Joachim Gerss; Christian Hagel; Haoyang Cai; Marc Remke; Martin Hasselblatt; Burt G Feuerstein; Sarah Pernet; Olivier Delattre; Andrey Korshunov; Stefan Rutkowski; Stefan M Pfister; Michael Baudis Journal: J Neurooncol Date: 2012-07-07 Impact factor: 4.130
Authors: A Jouvet; G Saint-Pierre; F Fauchon; K Privat; E Bouffet; M M Ruchoux; L Chauveinc; M Fèvre-Montange Journal: Brain Pathol Date: 2000-01 Impact factor: 6.508
Authors: Toshinori Hasegawa; Douglas Kondziolka; Constantinos G Hadjipanayis; John C Flickinger; L Dade Lunsford Journal: Neurosurgery Date: 2002-10 Impact factor: 4.654
Authors: A Jouvet; M Fèvre-Montange; R Besançon; E Derrington; G Saint-Pierre; M F Belin; J Pialat; C Lapras Journal: Acta Neuropathol Date: 1994 Impact factor: 17.088
Authors: Johannes Lutterbach; François Fauchon; Steven E Schild; Susan M Chang; Axel Pagenstecher; Benedikt Volk; Christoph Ostertag; Felix Momm; Anne Jouvet Journal: Neurosurgery Date: 2002-07 Impact factor: 4.654
Authors: Julieann C Lee; Tali Mazor; Richard Lao; Eunice Wan; Alpha B Diallo; Nicholas S Hill; Naina Thangaraj; Katherine Wendelsdorf; David Samuel; Cassie N Kline; Anuradha Banerjee; Kurtis Auguste; Corey Raffel; Nalin Gupta; Mitchel Berger; David R Raleigh; Anny Shai; Joanna J Phillips; Andrew W Bollen; Tarik Tihan; Arie Perry; Joseph Costello; David A Solomon Journal: Acta Neuropathol Date: 2019-03-14 Impact factor: 17.088
Authors: Cassie N Kline; Nancy M Joseph; James P Grenert; Jessica van Ziffle; Eric Talevich; Courtney Onodera; Mariam Aboian; Soonmee Cha; David R Raleigh; Steve Braunstein; Joseph Torkildson; David Samuel; Michelle Bloomer; Alejandra G de Alba Campomanes; Anuradha Banerjee; Nicholas Butowski; Corey Raffel; Tarik Tihan; Andrew W Bollen; Joanna J Phillips; W Michael Korn; Iwei Yeh; Boris C Bastian; Nalin Gupta; Sabine Mueller; Arie Perry; Theodore Nicolaides; David A Solomon Journal: Neuro Oncol Date: 2017-05-01 Impact factor: 12.300
Authors: Panagiotis Kerezoudis; Yagiz Ugur Yolcu; Nadia N Laack; Michael W Ruff; Soumen Khatua; David J Daniels; Terry C Burns; Sani H Kizilbash Journal: Neurooncol Adv Date: 2022-04-17
Authors: Joo Yeon Nam; Andrea Gilbert; David Cachia; Jacob Mandel; Gregory N Fuller; Marta Penas-Prado; John de Groot; Carlos Kamiya-Matsuoka Journal: Neurooncol Pract Date: 2020-05-12
Authors: Victor M Lu; Evan M Luther; Daniel G Eichberg; Alexis A Morell; Ashish H Shah; Ricardo J Komotar; Michael E Ivan Journal: J Neurooncol Date: 2021-10-04 Impact factor: 4.130
Authors: Amanda R Clark; David Calligaris; Michael S Regan; Daniel Pomeranz Krummel; Jeffrey N Agar; Laura Kallay; Tobey MacDonald; Matthew Schniederjan; Sandro Santagata; Scott L Pomeroy; Nathalie Y R Agar; Soma Sengupta Journal: J Neurooncol Date: 2018-08-20 Impact factor: 4.130
Authors: Anthony P Y Liu; Bryan K Li; Elke Pfaff; Brian Gudenas; Alexandre Vasiljevic; Brent A Orr; Christelle Dufour; Matija Snuderl; Matthias A Karajannis; Marc K Rosenblum; Eugene I Hwang; Ho-Keung Ng; Jordan R Hansford; Alexandru Szathmari; Cécile Faure-Conter; Thomas E Merchant; Max Levine; Nancy Bouvier; Katja von Hoff; Martin Mynarek; Stefan Rutkowski; Felix Sahm; Marcel Kool; Cynthia Hawkins; Arzu Onar-Thomas; Giles W Robinson; Amar Gajjar; Stefan M Pfister; Eric Bouffet; Paul A Northcott; David T W Jones; Annie Huang Journal: Acta Neuropathol Date: 2021-02-22 Impact factor: 15.887